Research and Development

We understand that only the most dedicated researchers, world-class facilities, and highest standards in science, quality, and ethics, will deliver the results we need for our patients – and help fulfil more unmet needs. That’s why over the past five years we’ve reinvested 25% of our profits into our facilities and research and development. Our R&D capabilities are recognized worldwide, from pre-clinical research through all phases of clinical development with proven expertise and focus in cancer care.


Our growing pipeline includes first-in-class therapies aimed at providing new solutions where no options currently exist, and helping to lift the burden of cancer for patients. 


Late Phase Development

We currently have an active pipeline of new cancer care products in various stages of development, including compounds in Phase III clinical development.

Learn more